SCHEMBL1567597

SCHEMBL1567597

[O]C(=O)C1COc2ccccc2O1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 4/20 0.61
ALDH1A1 P00352 2/20 0.61
SMN1; SMN2 Q16637 1/20 0.61
NISCH Q9Y2I1 1/20 0.61
POLB P06746 3/20 0.58
HTT P42858 2/20 0.56
CYP2C19 P33261 1/20 0.56
NPC1 O15118 2/20 0.55
RAB9A P51151 2/20 0.55
L3MBTL1 Q9Y468 2/20 0.55
MEN1 O00255 1/20 0.54
KMT2A Q03164 1/20 0.54
ALOX15 P16050 1/20 0.54
RECQL P46063 1/20 0.54
NPSR1 Q6W5P4 1/20 0.54
HSD17B10 Q99714 1/20 0.54
TDP1 Q9NUW8 1/20 0.54
KDM4E B2RXH2 1/20 0.54
PKM P14618 1/20 0.54
ROCK2 O75116 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3568567 0.86 HPGD (0.63) HPGDALDH1A1SMN1; SMN2NISCHPOLB
SCHEMBL30946854 0.85 NISCH (0.71) HPGDALDH1A1SMN1; SMN2NISCHPOLB
SCHEMBL229498 0.85 HPGD (0.61) HPGDALDH1A1SMN1; SMN2NISCHPOLB
SCHEMBL1300333 0.85 HPGD (0.61) HPGDALDH1A1SMN1; SMN2NISCHPOLB
SCHEMBL566636 0.85 HPGD (0.61) HPGDALDH1A1SMN1; SMN2NISCHPOLB
SCHEMBL29437007 0.85 HPGD (0.61) HPGDALDH1A1SMN1; SMN2NISCHPOLB
SCHEMBL2977327 0.85 NISCH (0.71) HPGDALDH1A1SMN1; SMN2NISCHPOLB
SCHEMBL407262 0.83 HPGD (0.59) HPGDALDH1A1SMN1; SMN2NISCHPOLB
SCHEMBL567872 0.83 HPGD (0.59) HPGDALDH1A1SMN1; SMN2NISCHPOLB
Hydrochloric Acid SCHEMBL7528728 0.83 HPGD (0.59) HPGDALDH1A1SMN1; SMN2NISCHPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3871673-B1 NOVEL INDAZOLE COMPOUND OR SALT THEREOF TAIHO PHARMACEUTICAL CO LTD (JP) 2024-01-03 EP disclosed
US-11696917-B2 Agent enhancing antitumor effect using pyrazolo[3,4-d]pyrimidine compound TAIHO PHARMACEUTICAL CO., LTD. (JP) 2023-07-11 US disclosed
US-20230181536-A1 ANTICANCER COMBINATION THERAPY WITH N-(1-ACRYLOYL-AZETIDIN-3-YL)-2-((1H-INDAZOL-3-YL)AMINO)METHYL)-1H-IMIDAZOLE-5-CARBOXAMIDE INHIBITOR OF KRAS-G12C TAIHO PHARMACEUTICAL CO LTD (JP) 2023-06-15 US disclosed
EP-3632443-B1 ANTI-TUMOR EFFECT POTENTIATOR USING A BIPHENYL COMPOUND TAIHO PHARMACEUTICAL CO LTD (JP) 2023-06-07 EP disclosed
US-20230064254-A1 THERAPEUTIC AGENT CONTAINING FUSED PYRIMIDINE COMPOUND AS ACTIVE INGREDIENT TAIHO PHARMACEUTICAL CO., LTD. (JP) 2023-03-02 US disclosed
US-20230049402-A1 NOVEL PHENOL COMPOUND OR SALT THEREOF TAIHO PHARMACEUTICAL CO. LTD. (JP) 2023-02-16 US disclosed
US-20230023023-A1 4-AMINOBUT-2-ENAMIDE DERIVATIVES AND SALTS THEREOF ASTEX THERAPEUTICS LIMITED (GB) 2023-01-26 US disclosed
EP-3381896-B1 BIPHENYL COMPOUND OR SALT THEREOF TAIHO PHARMACEUTICAL CO LTD (JP) 2023-01-18 EP disclosed
US-11236096-B2 Fused pyrimidine compound or salt thereof TAIHO PHARMACEUTICAL CO., LTD. (JP) 2022-02-01 US disclosed
US-20210395234-A1 NOVEL INDAZOLE COMPOUND OR SALT THEREOF TAIHO PHARMACEUTICAL CO. LTD. (JP) 2021-12-23 US disclosed
US-20120122797-A1 PEPTIDIC COMPOUND AND USE OF SAME KEIO UNIVERSITY (JP) 2012-05-17 US disclosed
US-20110251393-A1 HELICENE DERIVATIVE, AXIALLY ASYMMETRIC AMINO ACID, AMINE OR AMINOALCOHOL DERIVATIVE, PERYLENE DERIVATIVE OR SALT THEREOF, AND METHODS FOR PRODUCING SAME KYOTO UNIVERSITY (JP) 2011-10-13 US disclosed
US-20110226622-A1 NOVEL CLEAR NATIVE ELECTROPHORESIS METHOD UTILIZING AROMATIC SULFONIC ACID COMPOUND JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) 2011-09-22 US disclosed
EP-2357469-A1 NOVEL CLEAR NATIVE ELECTROPHORESIS METHOD UTILIZING AROMATIC SULFONIC ACID COMPOUND Japan Science and Technology Agency (JP) 2011-08-17 EP disclosed
EP-2357177-A1 HELICENE DERIVATIVE, AXIALLY ASYMMETRIC AMINO ACID, AMINE OR AMINOALCOHOL DERIVATIVE, PERYLENE DERIVATIVE OR SALT THEREOF, AND METHODS FOR PRODUCING SAME Kyoto University (JP) 2011-08-17 EP disclosed
US-20110117651-A1 CELL ADHESION PROMOTING AGENT AND METHOD OF PROMOTING CELL ADHESION KYOTO UNIVERSITY (JP) 2011-05-19 US disclosed
EP-2308960-A1 CELL ADHESION PROMOTING AGENT AND METHOD OF PROMOTING CELL ADHESION Kyoto University (JP) 2011-04-13 EP disclosed
US-7514452-B2 2-furancarboxylic acid hydrazides and pharmaceutical compositions containing the same DAINIPPON PHARMACEUTICAL CO., LTD (JP) 2009-04-07 US disclosed
US-20050171196-A1 2-Furancarboxylic acid hydrazides and pharmaceutical compositions containing the same DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2005-08-04 US disclosed
EP-1489077-A1 2-FURANCARBOXYLIC ACID HYDRAZIDES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME DAINIPPON PHARMACEUTICAL CO., LTD. (JP) 2004-12-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11236096-B2 Fused pyrimidine compound or salt thereof RET, RB1, MECP2 HPGD 3842/4885ALDH1A1 1942/4885SMN1; SMN2 1498/4885
US-20120122797-A1 PEPTIDIC COMPOUND AND USE OF SAME ASNS, ANPEP, NGLY1 HPGD 3902/4885ALDH1A1 4306/4885SMN1; SMN2 4730/4885
US-20110251393-A1 HELICENE DERIVATIVE, AXIALLY ASYMMETRIC AMINO ACID, AMINE OR AMINOALCOHOL DERIVATIVE, PERYLENE DERIVATIVE OR SALT THEREOF, AND METHODS FOR PRODUCING SAME AADAT, AASDHPPT, AZI2 HPGD 1393/4885ALDH1A1 976/4885SMN1; SMN2 3613/4885
US-20230023023-A1 4-AMINOBUT-2-ENAMIDE DERIVATIVES AND SALTS THEREOF KRAS, NRAS, HRAS HPGD 1462/4885ALDH1A1 2807/4885SMN1; SMN2 1891/4885
US-20110117651-A1 CELL ADHESION PROMOTING AGENT AND METHOD OF PROMOTING CELL ADHESION EPCAM, HDGF, DSC1 HPGD 939/4885ALDH1A1 974/4885SMN1; SMN2 4095/4885
US-11696917-B2 Agent enhancing antitumor effect using pyrazolo[3,4-d]pyrimidine compound ZYX, DPYD, ZFX HPGD 1886/4885ALDH1A1 2259/4885SMN1; SMN2 2489/4885
US-20110226622-A1 NOVEL CLEAR NATIVE ELECTROPHORESIS METHOD UTILIZING AROMATIC SULFONIC ACID COMPOUND IK, CHAMP1, RAB5IF HPGD 3727/4885ALDH1A1 3839/4885SMN1; SMN2 4187/4885
US-20050171196-A1 2-Furancarboxylic acid hydrazides and pharmaceutical compositions containing the same GLP1R, GCGR, GPR119 HPGD 299/4885ALDH1A1 1389/4885SMN1; SMN2 3697/4885
US-20230064254-A1 THERAPEUTIC AGENT CONTAINING FUSED PYRIMIDINE COMPOUND AS ACTIVE INGREDIENT GNAQ, REN, GLS HPGD 116/4885ALDH1A1 3279/4885SMN1; SMN2 3558/4885
US-20230181536-A1 ANTICANCER COMBINATION THERAPY WITH N-(1-ACRYLOYL-AZETIDIN-3-YL)-2-((1H-INDAZOL-3-YL)AMINO)METHYL)-1H-IMIDAZOLE-5-CARBOXAMIDE INHIBITOR OF KRAS-G12C KRAS, NRAS, HRAS HPGD 2609/4885ALDH1A1 1049/4885SMN1; SMN2 384/4885
US-20230049402-A1 NOVEL PHENOL COMPOUND OR SALT THEREOF MYB, MLX, EP300 HPGD 4347/4885ALDH1A1 235/4885SMN1; SMN2 3158/4885
US-20210395234-A1 NOVEL INDAZOLE COMPOUND OR SALT THEREOF HDAC11, RCOR3, BICRA HPGD 4011/4885ALDH1A1 521/4885SMN1; SMN2 3903/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.